ClearOne, Inc. (CLRO) Company Overview

What does ClearOne do today?

ClearOne, Inc. trades on the Nasdaq Capital Market under CLRO, but its 2026 economics differ sharply from the communications-equipment company many readers remember. In October 2025 it sold the intellectual property, inventory, product designs, brands, and selected customer-data rights tied to its conferencing business to Biamp. Continuing operations now center on legacy support, residual collections, public-company compliance, and a strategic transaction.

A listed transition vehicle, not an operating AV vendor

The latest Form 10-Q for the quarter ended March 31, 2026 states that ClearOne does not expect material revenue from continuing operations in the foreseeable future. That makes the company closer to a listed corporate platform with residual liabilities and a pending transaction than to a conventional product company. Historic descriptions of ClearOne as a global provider of microphones, audio conferencing, video collaboration, and network streaming remain useful for understanding the asset base that was sold, but they no longer describe the current revenue engine.

How did ClearOne make money before the asset sale?

Before October 2025, ClearOne earned mainly product revenue from audio conferencing systems, beamforming microphones, speakerphones, cameras, collaboration bundles, and network-streaming equipment sold through distributors and integrators. Revenue was generally recognized when equipment control transferred. Software and licensing were minor, so economics depended on unit volume, channel inventory, product mix, manufacturing cost, and meeting-room refresh cycles.

Which products generated the last meaningful quarterly revenue?

In Q1 2025, the final comparable quarter before the disposition, discontinued-operations revenue was $2.313 million. Microphones contributed $1.118 million, audio conferencing contributed $0.953 million, and video products contributed $0.242 million. The mix illustrates why ClearOne’s historical identity centered on installed professional audio rather than recurring software.

Why geography mattered

ClearOne’s old model was globally distributed. Q1 2025 revenue was $1.188 million in Asia Pacific, including the Middle East, India, and Australia; $0.960 million in the Americas; and $0.165 million in Europe and Africa. International reach expanded the addressable market but increased dependence on distributors, local demand, product localization, and a competitively priced U.S.-dollar product set.

What does ClearOne’s latest reported quarter show?

The latest quarter is best read as a cost-of-carry statement. Continuing operations generated no revenue, recorded $0.070 million of residual cost of goods sold, and incurred $0.780 million of general and administrative expense, producing a $0.850 million operating loss. Discontinued operations contributed $0.363 million of net income, reducing the consolidated net loss to $0.487 million.

Why the cash-flow statement is more informative than the income statement

ClearOne used $0.680 million of cash in continuing operations during Q1 2026, down from $2.644 million in Q1 2025 after the operating business was sold. Financing supplied $1.728 million. At March 31, 2026, cash was $0.756 million and restricted cash was $0.297 million; restricted funds were earmarked for legal, advisory, audit, severance, shutdown, and compliance milestones.

Which turning points explain ClearOne’s current strategy?

ClearOne evolved from specialist communications hardware into a cash-constrained public vehicle seeking a full reset. Its official investor FAQ dates incorporation to 1983 and public status to 1989. Acquisitions broadened the technology stack, but revenue contraction, margin pressure, cash distributions, and the 2025 disposal changed the company’s purpose.

1. 1983–1989
   The company was incorporated and then became public, establishing the listed entity that remains strategically valuable today.
2. 2009
   The NetStreams acquisition added networked digital-media and AV-over-IP capabilities, broadening ClearOne beyond conventional conferencing.
3. 2012
   The $4.6 million VCON asset acquisition expanded software-based video conferencing and infrastructure technology.
4. 2022–2023
   Derek Graham moved from long-time R&D leadership to CEO as the company confronted declining demand, supply disruption, and high fixed costs.
5. 2023–2024
   Large litigation and license proceeds supported special cash dividends, while core revenue fell from $18.704 million in 2023 to $11.386 million in 2024.
6. June–October 2025
   A 15-for-1 reverse split, restructuring, preferred-stock mechanics, and the $3.0 million Biamp asset sale ended the old operating model.
7. April–July 2026
   ClearOne reincorporated in Nevada and signed the Cortigent merger agreement, proposing a shift into implanted neurostimulation devices.

The decline before the sale

The decline preceded the disposal. Revenue fell from $25.205 million in 2022 to $18.704 million in 2023, $11.386 million in 2024, and $6.009 million in 2025 discontinued operations. Management cited weaker video demand, manufacturing-transition shortages, channel disruption, and pricing pressure, making a sale more rational than continued standalone investment.

What competitive advantage does ClearOne still have?

ClearOne’s former advantage came from acoustic echo cancellation, signal processing, beamforming microphones, patents, and specialized distribution. Leadership materials note that CEO Derek Graham is a named inventor on 13 patents, while earlier filings described more than 100 patents and pending applications. The October 2025 sale transferred key intellectual property, brands, designs, and inventory to Biamp, so that historic moat no longer belongs to CLRO shareholders.

Who are ClearOne’s competitors now?

Historically, ClearOne competed with professional-audio and collaboration vendors, including Biamp and Shure, on microphone arrays, digital signal processing, room systems, and intellectual property. That comparison is now backward-looking. After the sale, ClearOne has no meaningful product revenue and no conventional operating market share. Its practical competition is for scarce financing, Nasdaq compliance, credible transaction partners, and investor attention among micro-cap issuers pursuing reverse mergers or development-stage combinations.

Why the public listing matters

A functioning public listing can lower the structural barrier for a private technology company seeking public capital, but only if compliance is maintained. ClearOne disclosed that it was below Nasdaq’s quantitative continued-listing standards and received a formal notice in April 2026. The listing is therefore both the company’s most important surviving strategic asset and one of its most immediate vulnerabilities.

How financially strong is ClearOne?

ClearOne’s balance sheet is small. At March 31, 2026, total assets were $2.017 million, liabilities were $1.485 million, and shareholders’ equity was $0.532 million, up from negative $0.714 million at year-end 2025 after the March placement. No convertible-note liability remained, but cash was still modest relative to corporate and transaction costs.

What did the 2025 annual report reveal?

The 2025 Form 10-K showed the cost of exiting the old business. Discontinued-operations revenue was $6.009 million, gross loss was $3.021 million, operating loss was $10.317 million, and the loss on sale was $11.143 million. Consolidated net loss reached $26.084 million. Continuing operations used $14.554 million of cash during 2025, while financing provided $3.966 million. Total assets fell from $26.544 million at year-end 2024 to $2.299 million at year-end 2025.

Who owns ClearOne stock, and why does control matter?

ClearOne has a concentrated ownership structure. As of March 31, 2026, First Finance Ltd. beneficially owned 1,641,162 common shares, or approximately 61.3% of the common stock on an as-converted basis. Edward D. Bagley held 142,669 shares including exercisable options, equal to about 5.3%. Directors and executive officers as a group held only 19,124 shares including securities exercisable within 60 days, about 0.09% under the company’s table.

How did First Finance obtain influence?

First Finance’s position grew through a $3.0 million convertible note issued in June 2025, conversion into preferred stock, purchase of 700,000 shares from Edward Bagley in November 2025, and a March 2026 private placement. The March placement issued 437,500 common shares at $4.00 per share and a warrant for another 437,500 shares at $5.00, generating $1.750 million of gross proceeds. First Finance also has the right to nominate two directors.

Governance changed with the Nevada reincorporation

Stockholders holding about 61% of voting power and about 53% of the Class A preferred stock approved reincorporation by written consent. The Schedule 14C information statement explains that Nevada law differs from Delaware law regarding fiduciary duties, stockholder rights, and anti-takeover provisions. For minority holders, concentrated control means strategic outcomes can be decided without a broadly contested vote.

How would the Cortigent merger transform ClearOne?

The July 2026 merger agreement would change ClearOne’s sector, leadership, ownership, capital needs, and valuation method. Vivani-owned Cortigent develops implanted neurostimulation devices. Its predecessor commercialized the Argus II retinal prosthesis; the investigational Orion cortical system targets broader causes of blindness, while another program addresses arm and hand recovery after stroke.

What exactly is being proposed?

Under the July 2026 Form 8-K, Cortigent would become a wholly owned ClearOne subsidiary and Vivani would receive 12.5 million CLRO shares. ClearOne would be renamed Cortigent Holdings, Inc., do business as Cortigent, and is expected to trade under CRGT. A five-member board would include Adam Mendelsohn as chairman, Jonathan Adams, John Bowers, Linda Szyper, and Eric Robinson. Jonathan Adams would become president and CEO, while Ed Sedo would become CFO.

Why Cortigent could be strategically meaningful

The official transaction announcement says Orion received FDA Breakthrough Device Designation and completed a six-year early-feasibility study in 2025 with encouraging tolerability and clinical-activity observations. That creates a potential platform story based on neuroscience, implantable electronics, clinical evidence, and intellectual property. It also introduces the long timelines, regulatory uncertainty, trial costs, reimbursement questions, and repeated financing needs typical of development-stage medical devices.

What opportunities and risks could change the ClearOne story?

The opportunity is to convert a low-revenue listed shell into a funded neurotechnology company. The risk is that closing requires stockholder approvals, an effective registration statement, $10 million to $15 million of financing, minimum net cash, and continued Nasdaq listing. Failure on any condition could leave ClearOne with corporate costs and no replacement business.

Why is ClearOne difficult to value with a conventional DCF?

A normal DCF starts with operating revenue, margins, reinvestment, and free cash flow. ClearOne has no material continuing revenue, negative operating cash flow, limited liquidity, and a proposed transaction that would replace the business. Modeling the old AV operations would be wrong; modeling Cortigent as already closed would ignore financing, approval, listing, and execution probabilities.

A transaction-scenario framework is more appropriate

The more defensible approach separates the current entity from the proposed combined company. First estimate ClearOne’s available cash, restricted cash, remaining liabilities, transaction costs, and expected cash burn through closing. Then model the probability and timing of the merger. For the post-close case, build a fully diluted share count that includes 12.5 million consideration shares, financing shares and warrants, 855,000 advisor shares, up to 1.4 million options, existing warrants, and current common shares. Finally, value Cortigent through milestone-adjusted scenarios rather than a single smooth revenue curve.

Which KPIs matter most after closing?

Valuation method must follow economic substance. ClearOne is a transaction-dependent micro-cap, not a mature communications company and not yet an operating neurotechnology issuer. Scenario analysis, probability weighting, cash burn, and dilution modeling are more useful than a stable terminal-growth formula applied to zero current revenue.

What is the key takeaway from ClearOne analysis?

ClearOne shows how a public company can move from products to an asset-sale shell and then attempt a reverse-merger-style transformation. The former AV business had technology, patents, distribution, and recognizable products, but revenue fell, margins deteriorated, and the assets were sold. The surviving company has modest cash, concentrated control, ongoing compliance costs, and a Nasdaq listing that is both valuable and vulnerable.

The proposed Cortigent transaction offers a new purpose: neurostimulation for vision and motor-function recovery. It also replaces hardware economics with development-stage medical-device uncertainty. The combined company would need financing, clinical execution, regulatory progress, and careful dilution management. Existing CLRO holders are expected to retain only 12.7% to 14.4% before additional instruments.